Cargando…

Small-fiber polyneuropathy (SFPN), a common underlying diagnosis in syndromes involving unexplained chronic pain and multi-system symptoms

Detalles Bibliográficos
Autores principales:	Oaklander, Anne Louise, Downs, Heather, Herzog, Zeva Daniela, Klein, Max
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4304354/ http://dx.doi.org/10.1186/1744-8069-10-S1-O12

Ejemplares similares

Specific symptoms may discriminate between fibromyalgia patients with vs without objective test evidence of small-fiber polyneuropathy
por: Lodahl, Mette, et al.
Publicado: (2017)

IVIg for apparently autoimmune small-fiber polyneuropathy: first analysis of efficacy and safety
por: Liu, Xiaolei, et al.
Publicado: (2018)

Association of small-fiber polyneuropathy with three previously unassociated rare missense SCN9A variants
por: Kelley, Mary A., et al.
Publicado: (2020)

Evaluating Commonalities Across Medically Unexplained Symptoms
por: Guo, Dan, et al.
Publicado: (2019)

Epidemiology of Familial Amyloid Polyneuropathy in Bulgaria
por: Sarafov, Stayko, et al.
Publicado: (2015)

Familial amyloidotic polyneuropathy in Crete, Greece
por: Tzagournissakis, Minas, et al.
Publicado: (2015)

Psychopathological dimensions in familial amyloid polyneuropathy patients
por: Lopes, Alice, et al.
Publicado: (2015)

Ocular manifestations of transthyretin-related familial amyloid polyneuropathy
por: Rousseau, Antoine, et al.
Publicado: (2015)

Vasculopathy in transthyretin Val30Met familial amyloid polyneuropathy
por: Koike, Haruki, et al.
Publicado: (2015)

Langerhans cell activation in diabetic small fiber polyneuropathy
por: Piccione, Ezequiel Agustin, et al.
Publicado: (2014)

Transthyretin familial amyloid polyneuropathy impact on health-related quality of life
por: Inês, Mónica, et al.
Publicado: (2015)

Clinical, epidemiological, genetic, and electrophysiological characteristics of transthyretin familial amyloid polyneuropathies in Israel
por: Sadeh, Menachem, et al.
Publicado: (2015)

The hidden story behind gender differences in familial amyloid polyneuropathy (FAP) ATTRV30M
por: Santos, Diana, et al.
Publicado: (2015)

Familial Amyloid Polyneuropathy treatment with Tafamidis – evaluation of one- and two-year treatment in Porto, Portugal
por: Coelho, Teresa, et al.
Publicado: (2015)

Quantitative MR-neurographic parameters can determine and specify nerve injury in amyloid related polyneuropathy
por: Kollmer, Jennifer, et al.
Publicado: (2015)

Repetitive transcranial magnetic stimulation (rTMS) of the primary motor cortex for treating facial neuropathic pain – preliminary results of a randomized, sham-controlled, cross-over study
por: Lang, Magdalena, et al.
Publicado: (2014)

Medically unexplained neurological symptoms
por: Marcus, Hani, et al.
Publicado: (2010)

Non-invasive Transcranial Magnetic Stimulation (TMS) of the Motor Cortex for Neuropathic Pain—At the Tipping Point?
por: Treister, Roi, et al.
Publicado: (2013)

Phase 2 open-label extention (OLE) study of patisiran, an investigational siRNA agent for familial amyloidotic polyneuropathy (FAP)
por: Adams, David, et al.
Publicado: (2015)

Reassurance: Medically Unexplained Physical Symptoms
por: Anderson, Bill
Publicado: (2006)

Ion channels and neuropathic pain
por: Klein, Madeleine C, et al.
Publicado: (2018)

Facial nerve involvement in critical illness polyneuropathy
por: Gurjar, Mohan, et al.
Publicado: (2010)

Quality of life in polyneuropathy: association with biomarkers of small fiber impairment
por: Lin, Meng-Ting, et al.
Publicado: (2015)

Fibromyalgia syndrome and small fiber, early or mild sensory polyneuropathy
por: Lawson, Victoria H., et al.
Publicado: (2018)

Classification and Diagnosis of Patients with Medically Unexplained Symptoms
por: Smith, Robert C., et al.
Publicado: (2007)

Psychosocioeconomic Study of Medically Unexplained Physical Symptoms
por: Koola, Maju Mathew, et al.
Publicado: (2012)

The resource utilisation of medically unexplained physical symptoms
por: Lee, Kimberley, et al.
Publicado: (2016)

Medically Unexplained Symptoms (MUS): Faults and Implications
por: Tack, Michiel
Publicado: (2019)

Alexithymia among patients with unexplained physical symptoms
por: Rady, A., et al.
Publicado: (2021)

Focus on nerve fiber type: A diagnostic strategy for diabetic polyneuropathy
por: Hernandez Fustes, Otto Jesus
Publicado: (2020)

Analysis of Macrophages and Peptidergic Fibers in the Skin of Patients With Painful Diabetic Polyneuropathy
por: Gylfadottir, Sandra Sif, et al.
Publicado: (2021)

Patterns of myelinated nerve fibers loss in transthyretin amyloid polyneuropathy and mimics
por: Du, Kang, et al.
Publicado: (2022)

Psychosomatic symptoms related to exacerbation of fatigue in patients with medically unexplained symptoms
por: Hashimoto, Kazuaki, et al.
Publicado: (2022)

Evidence base for patient and public involvement in clinical trials (EPIC)
por: Gamble, Carrol, et al.
Publicado: (2013)

Analyzing the Problems in Managing Patients with Medically Unexplained Symptoms
por: Rief, Winfried
Publicado: (2007)

Models of unexplained symptoms associated with occupational and environmental exposures.
por: Spurgeon, Anne
Publicado: (2002)

War Syndromes: The Impact of Culture on Medically Unexplained Symptoms
por: JONES, EDGAR, et al.
Publicado: (2005)

Solving medical mysteries: hidden stresses and unexplained symptoms
por: Clarke, David D.
Publicado: (2016)

Assessment of Somatization and Medically Unexplained Symptoms in Later Life
por: van Driel, T. J. W., et al.
Publicado: (2017)

Prevalence of Disaccharidase Deficiency in Adults With Unexplained Gastrointestinal Symptoms
por: Viswanathan, Lavanya, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kj8lqecl8sim045q73hj4ho6rh